Freedom of Information Request 616-17

Freedom of Information Request 616-17

NHS Borders NHS Borders Education Centre Planning & Performance Borders General Hospital Melrose Roxburghshire TD6 9BD 01896 825545 [email protected] Freedom of Information request 616-17 Request I am writing to you today to ask: How many patients are currently being treated for moderate or severe atopic dermatitis (also known as eczema)? Please split these patients by their current drug treatment; Potent Topical Corticosteroids Corticosteroids Topical Potent therapies Immunosuppressive p ultraviolet (UVB) radiation or (UVB) radiation ultraviolet Phototherapy including with with including Phototherapy soralen-ultraviolet A soralen-ultraviolet Dupixient (dupilumab) Total Patients (see list below) below) list (see below) list (see Pimecrolimus Tacrolimus Alitretinoin Acitretin Treatment ( PUVA ) Number of Patients – currently on treatment for moderate-severe atopic dermatitis Potent Topical Corticosteroids [creams or ointments] • Amcinonide 0.05% (Cyclocort) • Betamethasone diproprionate 0.05% (Diprosone) • Betamethasone valerate • Clobetasol propionate • Desoximetasone 0.25% (Topicort) • Diflucortolone valerate • Fluocinonide 0.05% (Lidex) • Fluticasone proprionate 0.005% (Cutivate) • Halcinonide 0.05% (Halog) • Mometasone furoate 0.1% (Elocon ointment) • Triamcinalone acetonide 0.5% (Kenalog, Aristocort cream) • Betamethasone diproprionate 0.25% (Diprolene) • Clobetasol diproprionate 0.05% (Temovate) • Diflorasone diacetate 0.05% (Psorcon) • Halbetasol proprionate 0.05% (Ultravate) Immunosuppressive therapies • Azathioprine • Ciclosporin • methotrexate Response NHS Borders does not hold information on the number of patients who receive the above drugs as treatment for Atopical Dermatitis. The only information available is the number of prescriptions issued for any of these drugs but this does not indicate the number of patients prescribed these drugs for Atopical Dermatitis therefore under Section 17 of the FOI(S)A 2002 we cannot provide this as the information is not held. If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or [email protected]. The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number 616-17 on this request. Your request should be made within 40 working days from receipt of this letter. If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner is, Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife. .

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    2 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us